Senior partner in Neblett, Beard & Arsenault, was quoted in the Wall Street Journal today and appeared in the Wall Street Journal’s Law Blog over plans to seek compensation for victims of the Gulf of Mexico Oil Spill from the $20 billion oil spill fund, rather than proceeding with potentially lengthy litigation against BP and other parties.
A partners in his law firm, are among a group of approximately 30 lawyers who are moving their clients’ claims through the oil spill fund.
“Justice delayed is justice denied,” Attorney told the Journal’s Dionne Searcy.
The fund, which is administered by Ken Fienberg , and was set up by BP and the Obama administration, has already paid out $3.35 billion dollars to victims of the spill.
Victims of the oil spill are now deciding whether to opt for potentially quicker compensation through the oil spill fund, or to take their claims through the court system. Victims who seek compensation through the oil spill fund will be barred from filing a lawsuit, and may forfeit future damages that may be awarded by a court.
For many victims, waiting for a courtroom decision may not be possible. Daniel Becnel, a lawyer in Arsenault’s group, explained that many victims need compensation now to avert financial ruin and may not be capable of waiting for a result through litigation.Read Full
The popular, yet controversial, painkillers Darvon and Darvocet have been pulled from the market at the request of the FDA. New evidence has linked propoxyphene, the active ingredient in Darvon, Darvocet and their generic counterparts, with increased risk of serious, potentially fatal heart problems.
The FDA has determined that the drugs’ benefits do not outweigh the serious risks associated with the medications’ side effects, which include heart rhythm abnormalities. Even when taken at recommended doses by healthy patients, the propoxyphene in Darvon and Darvocet can still cause changes in the electrical activity of the heart that can cause serious problems, including sudden death.
Darvon was first introduced to the market. However, concerns over the drug’s serious side effects led consumer group, Public Citizen, to petition the FDA to remove the drug from the market. Darvon and Darvocet have been banned in the UK since 2005, and were banned in Europe over a year ago. Public Citizen estimates that as many as 1,000-2,000 US deaths have been linked to Darvon and/or Darvocet since the drugs were banned in England over 6 years ago.
Our drug injury lawyers know firsthand the pain and suffering that can be caused by unsafe pharmaceuticals. Our firm represented hundreds of Vioxx victims, and our senior partner, Attorneys, played a central role in the national litigation against Merck. We’ve been working hard for victims of dangerous drugs for nearly thirty years, and are currently investigating claims on behalf of victims of Darvon, Darvocet and generic propoxyphene painkillers.Read Full
The Food and Drug Administration announced that it issued Warning Letters to four companies that manufacture or distribute types of hand sanitizers and antiseptic products that inaccurately claim that they can prevent MSRA infections. The following four companies were issued Warning Letters:
1. Staphaseptic First Aid Antiseptic/Pain Relieving Gel, by Tec Laboratorie
2. Safe4Hours Hand Sanitizing Lotion and Safe4Hours First Aid Antiseptic Skin Protectant, by JD Nelson and Associates
3. Dr. Tichenor’s Antiseptic Gel, by Dr. G.H. Tichenor Antiseptic Co.
4. Clean Well All-Natural Hand Sanitizer, Clean Well All-Natural Hand Sanitizing Wipes, and Clean Well All-Natural Antibacterial Foaming Hand Soap, by Oh So Clean Inc., also known as CleanWell Company.
The FDA is concerned that these products are giving consumers a false sense of protection. Unproven claims found on product labels include, but are not limited to such claims as “kills over 99.9% of MRSA”; “helps prevent skin infections caused by MRSA and other germs”; “is effective against a broad spectrum of pathogens, including MRSA.”
MSRA is a very serious problem. It is a bacterium that can cause severe infections that may become life-threatening. Most troubling is that these infections do not respond to standard treatment with the antibiotic methicillin. According to Edward Cox, M.D., M.P.H., director of the FDA Office of Antimicrobial Products, MRSA is extremely difficult to treat.Read Full